Home » Newsletters » BioWorld Science

BioWorld Science

July 29, 1999

View Archived Issues

Genzyme Molecular Oncology reports Q2 1999 highlights

Important objectives achieved during Q2 at Alza

Avant Immunotherapeutics' rotavirus vaccine effective in infants

Abbott signs paclitaxel agreement with NaPro BioTherapeutics

Approval of Busulfex injection in Canada

Atugen Biotechnology establishes North American subsidiary

Targeted Genetics and Elan form drug delivery partnership

Inhibitex's U.S. patent for S. aureus attachment gene allowed

Irinotecan approved as first-line treatment for advanced colorectal cancer in Europe

EntreMed cleared to begin phase I trials of Endostatin protein

Novo Nordisk describes new K(ATP) channel-modulating series

Abbott prepares potent, selective neuronal nicotinic acetylcholine receptor ligands

Japanese investigators discover novel antitumor/antimicrobial agent produced by actinomycete

New muscarinic compounds from Alcon especially useful for Rx of glaucoma

AHP describes synthesis and activity of novel estrogenic compounds

Anthranilide anticoagulants developed by Schering AG researchers

Genetics Institute discovers and characterizes novel bone morphogenetic proteins

Millennium obtains patent coverage for novel weight-regulating compounds

Disaccharide ester with anti-TNF-alpha effects and chemopreventive efficacy

PABSA: preclinical profile of a newly developed nonpeptide ET antagonist

No adverse influence on cardiac repolarization seen in in vitro studies with tegaserod

Adolor and SmithKline Beecham sign licensing agreement for ADL-2-1294

Cangene product for prevention of hemolytic disease approved in U.K.

New thrombin inhibitor approved in Italy for antithrombotic prophylaxis

Marked, long-lasting neuroprotective effects demonstrated for NXY-059 in rats

FDA approves SB's Kytril for prevention of radiation-induced nausea and vomiting

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...